may 10, 2013 - FDA responded to a petition and the original formulation of Opana ER (oxymorphone hydrochloride) Extended-Release Tablets was not withdrawn from the market for reasons of safety or effectiveness. As a result, generic versions of the original formulation can continue to be approved and marketed.
Added to timeline:
Date:
may 10, 2013
Now
~ 13 years ago